Metamizol Gemax Pharma (Metamizole Sodium Monohydrate)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which reduces the production of prostaglandins—key mediators of pain, fever, and inflammation. Although the full mechanism is not completely understood, this inhibition leads to decreased sensitization of pain pathways and a lower hypothalamic set‑point for temperature regulation.

The specific dose of Metamizol Gemax Pharma is determined by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and clinical condition. Healthcare professionals adjust the regimen to achieve optimal pain relief or fever reduction while monitoring safety.

Safety data for Metamizol Gemax Pharma in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after a thorough risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metamizol Gemax Pharma belongs to the pyrazolone class, offering rapid analgesic and antipyretic effects similar to NSAIDs but with a distinct safety profile. Unlike some NSAIDs, it has a lower risk of gastrointestinal ulceration but carries a rare risk of agranulocytosis, which requires blood‑count monitoring.

Metamizol Gemax Pharma should be stored at room temperature, below 25 °C, in its original container. Protect the product from moisture, excessive heat, and direct sunlight to maintain its stability and potency throughout its shelf life.

Metamizol Gemax Pharma is administered orally. The tablet or liquid is taken with water, and the exact administration schedule is set by the prescribing clinician based on the therapeutic need and patient response.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection, skin rash, or breathing difficulties, and immediate medical attention is required if these occur.

Metamizol Gemax Pharma is contraindicated in individuals with a known hypersensitivity to metamizole or other pyrazolones, patients with a history of agranulocytosis, and those currently receiving other myelosuppressive therapies. It should also be used with caution in patients with severe renal or hepatic impairment.